Table 3.
Comparison of outcome measurement within groups.
| Measure | Control group | Intervention group | ||||||
|
|
|
T1a – T0b (95%CI) | Z value | P valuec | T1 – T0 | Z value | P valuec | |
| MUSEd |
|
|
|
|
|
|
||
|
|
All medications | 0.52 (–1.61-2.65) | –0.85 | .39 | 4.57 (1.94-7.19) | –3.63 | .001 | |
|
|
Hypertensivee | 1.26 (–0.36-2.89) | 1.79 | .07 | 4.35 (2.18-6.52) | –3.60 | <.001 | |
|
|
Antithromboticf | –0.91 (–1.29-3.11) | –0.37 | .71 | 3.70 (1.62-5.77) | –3.18 | .001 | |
| Systolic blood pressuree (mmHg) | –1.87 (–6.70 to –2.96) | 0.54 | .59 | –13.04 (–22.22 to –3.87) | –2.03 | .04 | ||
| Diastolic blood pressuree (mmHg) | 0.48 (–6.17-7.13) | –0.59 | .56 | –0.87 (–6.58-4.84) | –0.144 | .89 | ||
aT1: baseline (control group n=27, intervention group n=30).
bT0: baseline (control group n=27, intervention group n=30).
cWilcoxan signed-rank test
dMUSE: medication understanding and use self-efficacy.
ePrescribed with antihypertensive medication and diagnosed with hypertension as a primary factor (control group n=24, intervention group n=26).
fPrescribed antithrombotic as a prerequisite preventative treatment for stroke (control group n=27, intervention group n=27).